Kura Oncology, Inc. (FRA:KUR)
Germany · Delayed Price · Currency is EUR | Market Cap | 593.43M +9.7% |
| Revenue (ttm) | 57.47M +25.2% |
| Net Income | -237.34M |
| EPS | -2.71 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 15 |
| Open | 7.14 |
| Previous Close | 7.24 |
| Day's Range | 7.14 - 7.14 |
| 52-Week Range | 4.68 - 10.78 |
| Beta | n/a |
| RSI | 47.27 |
| Earnings Date | Apr 30, 2026 |
About Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n... [Read more]
Financial Performance
In 2025, Kura Oncology's revenue was $67.48 million, an increase of 25.24% compared to the previous year's $53.88 million. Losses were -$278.67 million, 60.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatmen...
Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript
Kura Oncology, Inc. (KURA) Q4 2025 Earnings Call Transcript
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, ...
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda...
Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda...
Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy
Kura Oncology is upgraded from buy to strong buy, driven by a compelling valuation reset and robust cash position. Komzifti's FDA approval for relapsed/refractory NPM1-mutated AML is de-risked; the tr...
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
– Launched KOMZIFTI ™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from firs...
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
Kura Oncology, Inc. (KURA) Discusses Ziftomenib Combination Data in Newly Diagnosed and Relapsed/Refractory NPM1-m and KMT2A-r AML Transcript
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and ove...
Kura Oncology: A Cautious Buy
Kura Oncology (KURA) is rated a cautious Speculative Buy, driven by Komzifti's FDA approval and frontline AML potential. KURA's near-term revenue under the current label is meaningful but insufficient...
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda...
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data
Kura Oncology remains a Strong Buy, driven by Ziftomenib's differentiated safety profile and significant AML market potential. KURA's Ziftomenib avoids a QTc prolongation boxed warning, offering a pot...
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of canc...
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated AML, is now commercially available in the United States KOMZIFTI, the first and only once-daily FDA-approved m...
Kura Oncology, Inc. (KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Transcript
Kura Oncology, Inc. ( KURA) Discusses FDA Approval of KOMZIFTI for Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia November 13, 2025 12:30 PM EST Company Participants Greg Mann Troy Wilson...
Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low survival rat...
US FDA approves Kura Oncology's blood cancer therapy
The U.S. Food and Drug Administration has approved Kura Oncology's drug to treat a rare form of blood cancer that has returned or resisted initial therapy, the regulator said on Thursday.
Kura Oncology to Participate in Upcoming Investor Conference
SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...
Kura Oncology, Inc. (KURA) Q3 2025 Earnings Call Transcript
Kura Oncology, Inc. ( KURA) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Greg Mann Thomas Doyle - Senior Vice President of Finance & Accounting Troy Wilson - Chairman, CEO ...
Kura Oncology Reports Third Quarter 2025 Financial Results
– New Drug Application for ziftomenib in adults with R/R NPM1-m AML remains under FDA Priority Review, with a PDUFA target action date of November 30, 2025 –
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
– Milestone triggered by dosing of first patient in the second of two frontline AML Phase 3 clinical trials – – Milestone triggered by dosing of first patient in the second of two frontline AML Phase ...
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use – SA...
Kura Oncology's Ziftomenib Poised For Differentiation
Kura Oncology is reiterated as a strong buy, due to Ziftomenib's potential best-in-class safety profile in NPM1-mutated AML. Recent FDA approval of Syndax's Revuforj included a boxed warning for cardi...
Kura Oncology to Report Third Quarter 2025 Financial Results
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment ...